Navigation Links
Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
Date:7/17/2008

% Growth % Growth

@ @

YTD YTD Actual Constant

2008 2007 Rates Rates

--------------------------------------------------------------------------

--------------------------------------------------------------------------

BioScience

Recombinants $944 $819 15% 9%

Plasma Proteins 551 468 18% 11%

Antibody Therapy 601 460 31% 26%

Regenerative Medicine (1) 203 169 20% 14%

Other (2) 296 346 (14%) (25%)

--------------------------------------------------------------------------

Total BioScience (3) $2,595 $2,262 15% 8%

--------------------------------------------------------------------------

--------------------------------------------------------------------------

Medication Delivery

IV Therapies $779 $666 17% 8%

Global Injectables 761 742 3% (2%)

Infusion Systems 449 417 8% 3%

Anesthesia 221 185 19% 15%

Other 19 19 0% (5%)

--------------------------------------------------------------------------

Total Medication Delivery $2,229 $2,029 10% 4%

--------------------------------------------------------------------------

--------------------------------------------------------------------------

Renal

PD Therapy
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
2. Baxters Board of Directors Declares Quarterly Dividend
3. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
4. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
5. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
6. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
7. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
8. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
9. Baxter Declares Quarterly Dividend
10. Baxter Provides Update on Heparin Reactions
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... DUBLIN, August 3, 2010 , - Proposed recommended cash acquisition ... a fully diluted equity purchase price of, EUR428 ... date, Movetis held EUR100 million in cash; based on this ... be EUR328 million, - Strong strategic fit with Shire,s growing ...
... ,, ROCKVILLE, Md. , Aug. 2 Vanda Pharmaceuticals Inc. ... the development and commercialization of products for central nervous system disorders, today announced ... August 5, 2010 , before the market opens. A full text copy of ... , , ...
... , CHICAGO and HOBOKEN, N.J. , Aug. 2 ... of the Octapharma 25th Anniversary Grants Program is the Rush ... Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies ... , , ...
Cached Biology Technology:Shire Proposes to Expand Specialist Gastrointestinal Portfolio 2Shire Proposes to Expand Specialist Gastrointestinal Portfolio 3Shire Proposes to Expand Specialist Gastrointestinal Portfolio 4Shire Proposes to Expand Specialist Gastrointestinal Portfolio 5Shire Proposes to Expand Specialist Gastrointestinal Portfolio 6Shire Proposes to Expand Specialist Gastrointestinal Portfolio 7Shire Proposes to Expand Specialist Gastrointestinal Portfolio 8Shire Proposes to Expand Specialist Gastrointestinal Portfolio 9Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6
(Date:7/11/2014)... Canyon fire started near the City of Entiat on ... resources, the fire quickly grew to over 1,000 acres ... the fire is under investigation by the Washington Department ... with existing local resources in developing fire control strategies ... (USFS), Washington State Department of Natural Resources, (WA DNR), ...
(Date:7/11/2014)... of Chicago is creating a new professorship in ... University,s Institute for Molecular Engineering and the Marine ... from the Millicent and Eugene Bell Foundation., The ... within the Institute for Molecular Engineering. That endowed ... at the MBL,s Eugene Bell Center for Regenerative ...
(Date:7/11/2014)... have set a "mouse TRAP" to capture the early ... study published in the Journal of Clinical Investigation ... called TRAP to extract cellular and genetic information from ... at the Rockefeller Institute for Medical Research in 2008, ... machinery, or ribosomes, of the cell type of interest. ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2
... HONOLULU While the iconic Haleakalā silversword plant made a ... a period of substantial climate-related decline. New research published this ... the silversword in its native habitat. Known for its ... single reproductive event at the end of its life, at ...
... structural similarity to asbestos, have been alleviated following research ... In a new study, published today in ... that the asbestos-like reactivity and pathogenicity reported for long, ... is modified and their effective length is reduced as ...
... DENVER Recent studies have demonstrated that molecular-targeted agents, ... inhibitors (TKI), may prolong survival of selected patients based ... EGFR gene is known as a predictive marker for ... EGFR mutations are prognostic factors for non-small cell lung ...
Cached Biology News:Global warming may have severe consequences for rare Haleakalā silverswords 2Chemistry resolves toxic concerns about carbon nanotubes 2EGFR mutation not prognostic factor in non-small cell lung cancer 2
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
...
Request Info...
Biology Products: